Investing.com -- Shares of NeoGenomics (NASDAQ: NASDAQ: NEO ) plunged 18% after the company issued full-year earnings per share (EPS) guidance that fell short of investor expectations.

The oncology diagnostics company reported a fourth-quarter EPS of $0.04, which was slightly better than the consensus estimate of $0.03. However, revenue for the quarter was $172 million, just shy of the consensus estimate of $173.05 million. Despite this, the company's full-year consolidated revenue increased 12% to $661 million.

For the upcoming fiscal year 2025, NeoGenomics anticipates an EPS of $0.15 to $0.19, compared to the consensus projection of $0.20. The company's revenue forecast for FY2025 stands at $735-745 million, aligning with the consensus of $735 million.

NeoGenomics' CEO, Chris Smith, highlighted the company's sustained double-digit revenue growth over nine consecutive quarters and a significant improvement in adjusted EBITDA, which surged by 1,036% to $40 million for the full year. Smith also pointed to the company's strong position for future growth, thanks to robust customer demand and upcoming product launches.

Despite these positive remarks, the stock's downturn reflects investor discontent with the EPS guidance for FY2025. Raymond (NSE: RYMD ) James analyst Andrew Cooper commented on the results, saying, "Our initial reaction is fairly muted as much of what was reported is near consensus, with the modest revenue noise offset by stronger EBITDA, though we don’t think the overall is particularly inspiring and the stock is indicating lower."

Investors will be watching closely for updates on NeoGenomics' NGS traction, the CEO transition, and progress on the commercial re-launch of RaDaR as the company moves forward.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.